Metabolic Disturbance

  • Pamela Carvalho Muniz
  • Mayndra Mychelle Landgraf
  • Fernando Silva Picon
  • Hakaru Tadokoro
  • Ramon Andrade De MelloEmail author
  • Michelle Samora de Almeida


As specific cancer treatments evolved, our ability to anticipate side effects and prevent them has also been refined. Prophylaxis allows us to avoid numerous metabolic alterations, but it is still a frightening terrain in view of its clinical consequences. Knowing deeply the diagnostic steps and their management is of fundamental importance in the daily routine of the caregiver (Lawrence TS, Rosenberg SA: DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. Lippincott Williams & Wilkins, Philadelphia, 2015).


Palliative care Supportive care Cancer 


  1. 1.
    Lawrence TS, Rosenberg SA (2015) DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  2. 2.
    Maier JD, Levine SN (2015) Hypercalcemia in the intensive care unit: a review of pathophysiology, diagnosis, and modern therapy. J Intensive Care Med 30(5):235–252CrossRefGoogle Scholar
  3. 3.
    Reagan P, Pani A, Rosner MH (2014) Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis 63(1):141–147CrossRefGoogle Scholar
  4. 4.
    Stewart AF (2005) Hypercalcemia associated with cancer. N Engl J Med 352(4):373–379CrossRefGoogle Scholar
  5. 5.
    Martins HS, Brandão Neto RA, Velasco IT (2016) Medicina de emergências: abordagem prática. Manole, BarueriGoogle Scholar
  6. 6.
    Pi J, Kang Y, Smith M, Earl M, Norigian Z, McBride A (2016) A review in the treatment of oncologic emergencies. J Oncol Pharm Pract 22(4):625–638CrossRefGoogle Scholar
  7. 7.
    Ahmad S, Kuraganti G, Steenkamp D (2015) Hypercalcemic crisis: a clinical review. Am J Med 128(3):239–245CrossRefGoogle Scholar
  8. 8.
    Daniels E, Sakakeeny C (2015) Hypercalcemia: pathophysiology, clinical signs, and emergent treatment. J Am Anim Hosp Assoc 51(5):291–299CrossRefGoogle Scholar
  9. 9.
    Sternlicht H, Glezerman IG (2015) Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag 11:1779PubMedPubMedCentralGoogle Scholar
  10. 10.
    LeGrand SB, Leskuski D, Zama I (2008) Narrative review: furosemide for hypercalcemia: an unproven yet common practice furosemide for hypercalcemia. Ann Intern Med 149(4):259–263CrossRefGoogle Scholar
  11. 11.
    Kawada K, Minami H, Okabe K, Watanabe T, Inoue K, Sawamura M et al (2005) A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 35(1):28–33CrossRefGoogle Scholar
  12. 12.
    Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen H et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19(2):558–567CrossRefGoogle Scholar
  13. 13.
    Wagner J, Arora S (2014) Oncologic metabolic emergencies. Emerg Med Clin North Am 32(3):509–525CrossRefGoogle Scholar
  14. 14.
    Mirrakhimov AE (2015) Hypercalcemia of malignancy: an update on pathogenesis and management. N Am J Med Sci 7(11):483–493CrossRefGoogle Scholar
  15. 15.
    Howard SC, Jones DP, Pui C-H (2011) The tumor lysis syndrome. N Engl J Med 2011(364):1844–1854CrossRefGoogle Scholar
  16. 16.
    Mirrakhimov AE, Voore P, Khan M, Ali AM (2015) Tumor lysis syndrome: a clinical review. World J Crit Care Med 4(2):130–138CrossRefGoogle Scholar
  17. 17.
    Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127(1):3–11CrossRefGoogle Scholar
  18. 18.
    Mughal TI, Ejaz AA, Foringer JR, Coiffier B (2010) An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 36(2):164–176CrossRefGoogle Scholar
  19. 19.
    Coiffier B, Altman A, Pui C-H, Younes A, Cairo MS (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26(16):2767–2778CrossRefGoogle Scholar
  20. 20.
    Edeani A, Shirali A (2016) Tumor lysis syndromeGoogle Scholar
  21. 21.
    Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA (2000) Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 18(8):1758–1763CrossRefGoogle Scholar
  22. 22.
    Wilson FP, Berns JS (2014) Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis 21(1):18–26CrossRefGoogle Scholar
  23. 23.
    Berghmans T, Paesmans M, Body J-J (2000) A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 8(3):192–197CrossRefGoogle Scholar
  24. 24.
    Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK (2012) Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 59(2):222–228CrossRefGoogle Scholar
  25. 25.
    Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH et al (2013) Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 126(10):S1–S42CrossRefGoogle Scholar
  26. 26.
    Ellison DH, Berl T (2007) The syndrome of inappropriate antidiuresis. N Engl J Med 356(20):2064–2072CrossRefGoogle Scholar
  27. 27.
    Yu Z, Parker KM, Blick KE (2005) Markedly decreased serum sodium concentration in a patient with multiple myeloma. Lab Med 36(4):224–226CrossRefGoogle Scholar
  28. 28.
    Chute JP, Taylor E, Williams J, Kaye F, Venzon D, Johnson BE (2006) A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res 12(3):888–896CrossRefGoogle Scholar
  29. 29.
    Peri A (2013) The use of vaptans in clinical endocrinology. J Clin Endocrinol Metabol 98(4):1321–1332CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Pamela Carvalho Muniz
    • 1
  • Mayndra Mychelle Landgraf
    • 2
  • Fernando Silva Picon
    • 3
  • Hakaru Tadokoro
    • 4
  • Ramon Andrade De Mello
    • 5
    • 6
    Email author
  • Michelle Samora de Almeida
    • 2
  1. 1.Department of Medical OncologyUniversidade Federal de São PauloSão PauloBrazil
  2. 2.Department of Medical Oncology, São Paulo University HospitalFederal University of São PauloSão PauloBrazil
  3. 3.Department of Medical Oncology, Escola Paulista de MedicinaUniversidade Federal de São PauloSão PauloBrazil
  4. 4.Division of Medical Oncology, Escola Paulista de MedicinaFederal University of São PauloSão PauloBrazil
  5. 5.Division of Medical OncologyFederal University of São Paulo (UNIFESP) & Hospital Israelita Albert EinsteinSão PauloBrazil
  6. 6.Department of Biomedical Sciences and MedicineUniversity of AlgarveFaroPortugal

Personalised recommendations